Printed From BioPortfolio.com
NHS England seals access deals with big pharma for breast cancer and MS
06:00 EST 9 Nov 2017 | Pharmafile
NHS England has entered into a commercial agreement with MSD which aims to provide access to innovative treatments for both multiple sclerosis and breast cancer, it has emerged. As part of the agreement with two major pharma firms, Merck’s multiple sclerosis treatment Mavenclad (cladribine tablets) will be made available to hundreds of patients effective 10 November, while an agreement in principle has been reached on the availability of Roche’s Perjeta (pertuzumab) by unlocking the final stage of NICE’s appraisal.
Original Article: NHS England seals access deals with big pharma for breast cancer and MS
